Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus chemotherapy as neoadjuvant therapy for HER2-negative breast cancer
ChiCTR2200058196Phase 4Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathologic Complete Response. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058196.